Last reviewed · How we verify
Azithromycin at Day 21
At a glance
| Generic name | Azithromycin at Day 21 |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vitality in Infants Via Azithromycin for Neonates Trial (PHASE4)
- Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children (NA)
- Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women - Mumta Pregnant Women Trial (NA)
- Nutritional Support for Lactating Women and Azithromycin to Infants - Mumta Lactating Women Trial (NA)
- Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients (NA)
- A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia (PHASE4)
- Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin at Day 21 CI brief — competitive landscape report
- Azithromycin at Day 21 updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI